Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q13155

UPID:
AIMP2_HUMAN

ALTERNATIVE NAMES:
Multisynthase complex auxiliary component p38; Protein JTV-1

ALTERNATIVE UPACC:
Q13155; F8W950; Q75MR1; Q96CZ5; Q9P1L2

BACKGROUND:
The Aminoacyl tRNA synthase complex-interacting multifunctional protein 2, known alternatively as Multisynthase complex auxiliary component p38 or Protein JTV-1, is pivotal in protein synthesis. It ensures the aminoacyl-tRNA synthase complex's assembly and stability, orchestrates the ubiquitination and degradation of FUBP1 to regulate MYC, and safeguards p53/TP53 from MDM2-mediated degradation, serving a proapoptotic role.

THERAPEUTIC SIGNIFICANCE:
Its association with Leukodystrophy, hypomyelinating, 17, underscores its therapeutic relevance. The protein's intricate involvement in this neurodevelopmental disorder suggests that deeper insights into its functions could pave the way for innovative therapeutic approaches.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.